146 related articles for article (PubMed ID: 37027485)
1. Homogeneous, Simple, and Direct Analysis of Exosomal PD-L1 via Aptamer-Bivalent-Cholesterol-Anchor Assembly of DNAzyme (ABCzyme) for Tumor Immunotherapy.
Hao J; Wang J; Dong Y; Yang J; Wang Z; Zhao X; Zeng T; Zhao X; Liang H; Li J
Anal Chem; 2023 May; 95(17):6854-6862. PubMed ID: 37027485
[TBL] [Abstract][Full Text] [Related]
2. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
3. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
4. Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy.
Rasihashemi SZ; Rezazadeh Gavgani E; Majidazar R; Seraji P; Oladghaffari M; Kazemi T; Lotfinejad P
J Cell Physiol; 2022 Mar; 237(3):1648-1660. PubMed ID: 34825383
[TBL] [Abstract][Full Text] [Related]
5. Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction.
Huang M; Yang J; Wang T; Song J; Xia J; Wu L; Wang W; Wu Q; Zhu Z; Song Y; Yang C
Angew Chem Int Ed Engl; 2020 Mar; 59(12):4800-4805. PubMed ID: 31912940
[TBL] [Abstract][Full Text] [Related]
6. Aptamer-bivalent-cholesterol-mediated proximity entropy-driven exosomal protein reporter for tumor diagnosis.
Fan Z; Zhou J; Shu Q; Dong Y; Li Y; Zhang T; Bai G; Yu H; Lu F; Li J; Zhao X
Biosens Bioelectron; 2024 May; 251():116104. PubMed ID: 38368644
[TBL] [Abstract][Full Text] [Related]
7. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
Shimada Y; Matsubayashi J; Kudo Y; Maehara S; Takeuchi S; Hagiwara M; Kakihana M; Ohira T; Nagao T; Ikeda N
Sci Rep; 2021 Apr; 11(1):7830. PubMed ID: 33837261
[TBL] [Abstract][Full Text] [Related]
8. The Detection of Exosomal PD-L1 in Peripheral Blood.
Wang R; Yang Y; Huang J; Yao Y
Methods Mol Biol; 2023; 2695():195-212. PubMed ID: 37450120
[TBL] [Abstract][Full Text] [Related]
9. The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.
Ye L; Zhu Z; Chen X; Zhang H; Huang J; Gu S; Zhao X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831468
[TBL] [Abstract][Full Text] [Related]
10. The role of exosomal PD-L1 in tumor progression and immunotherapy.
Xie F; Xu M; Lu J; Mao L; Wang S
Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
[TBL] [Abstract][Full Text] [Related]
11. Single-Step and Highly Sensitive Imaging of Exosomal PD-L1 through Aptamer-Activated Cascade Primer Exchange Reaction-Generated Branched DNA Nanostructures.
Li X; Li X; Cheng X; Bian X; Shen B; Ding X; Ding S
ACS Sens; 2022 Nov; 7(11):3571-3579. PubMed ID: 36329604
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
[TBL] [Abstract][Full Text] [Related]
13. Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer.
Zhang Z; Jin W; Xu K; Zheng X; Zhou Y; Luo M; Yan C; Zheng X; Jin E
Tissue Cell; 2022 Dec; 79():101941. PubMed ID: 36228365
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
[TBL] [Abstract][Full Text] [Related]
15. High Throughput and Noninvasive Exosomal PD-L1 Detection for Accurate Immunotherapy Response Prediction via Tim4-Functionalized Magnetic Core-Shell Metal-Organic Frameworks.
Wang H; Liu Y; Zhang L; Li X; Zhao G; Song Z; Jia Y; Qiao X
Anal Chem; 2023 Dec; 95(49):18268-18277. PubMed ID: 38011622
[TBL] [Abstract][Full Text] [Related]
16. The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer.
Tang Y; Zhang P; Wang Y; Wang J; Su M; Wang Y; Zhou L; Zhou J; Xiong W; Zeng Z; Zhou Y; Nie S; Liao Q
Front Immunol; 2020; 11():604. PubMed ID: 32322256
[TBL] [Abstract][Full Text] [Related]
17. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
Poggio M; Hu T; Pai CC; Chu B; Belair CD; Chang A; Montabana E; Lang UE; Fu Q; Fong L; Blelloch R
Cell; 2019 Apr; 177(2):414-427.e13. PubMed ID: 30951669
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer landscape of
Kelly AD; Murugesan K; Kuang Z; Montesion M; Ross JS; Albacker LA; Huang RSP; Lin DI; Demirci U; Creeden J
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815356
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Immunohistochemistry-Discrepant Results Between Synchronous Tumor Samples May Cause More Treatment Choice Dilemmas Than Molecular Heterogeneity in Patients With Advanced Non-Small Cell Lung Cancers.
Lambros L; Quintin-Roué I; Bourhis A; Remoué A; Le Flahec G; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Jul; 28(6):437-443. PubMed ID: 31498156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
